Usefulness of fecal calprotectin by monoclonal antibody testing in adult Japanese with inflammatory bowel diseases: a prospective multicenter study

Nakamura, Shirô; Imaeda, Hirotsugu; Nishikawa, Hiroki; Iimuro, Masaki; Matsuura, Minoru; Oka, Hideo; Oku, Junsuke; Miyazaki, Tatsuya; Honda, Hirohito; Watanabe, Kenji; Nakase, Hiroshi; Andoh, Akira

doi:10.5217/ir.2018.00027

Cited by 4 publications

(5 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The stool samples were collected within 2 days before the colonoscopic procedure. FC (Calprotectin Mochida, Mochida Pharmaceutical, Tokyo, Japan) was measured using enzyme‐linked immune sorbent assay kits 15 . All study data were sent to the statistician (Biostatistics Unit at Clinical and Translational Research Center, Keio University School of Medicine, Tokyo, Japan).…”

Section: Methodsmentioning

confidence: 91%

Mucosal concentrations of N‐acetyl‐5‐aminosalicylic acid related to endoscopic activity in ulcerative colitis patients with mesalamine

Fukuda

Takabayashi

Hagihara

et al. 2020

J of Gastro and Hepatol

View full text Add to dashboard Cite

Background and Aim 5‐Aminosalicylic acid (5‐ASA) is a fundamental treatment for mild‐to‐moderate ulcerative colitis (UC). 5‐ASA is taken up into the colonic mucosa and metabolized to N‐acetyl‐5‐ASA (Ac‐5‐ASA). Few studies have assessed whether mucosal 5‐ASA and Ac‐5‐ASA concentrations are associated with endoscopic remission. This study aimed to investigate differences in 5‐ASA and Ac‐5‐ASA concentrations according to endoscopic activity. Methods This single‐center, prospective, cross‐sectional study was conducted between March 2018 and February 2019. UC patients who were administered with 5‐ASA medication for at least 8 weeks before sigmoidoscopy were enrolled. Mucosal 5‐ASA and Ac‐5‐ASA concentrations were measured using liquid chromatography with tandem mass spectrometry. The primary endpoint was defined as the difference in mucosal concentrations of 5‐ASA and Ac‐5‐ASA, according to the Mayo endoscopic subscore (MES). Results Mucosal concentrations were analyzed in 50 patients. In the sigmoid colon, the median 5‐ASA concentration in patients with MES of 0 (17.3 ng/mg) was significantly higher than MES ≥ 1 (6.4 ng/mg) (P = 0.019). The median 5‐ASA concentrations in patients with Ulcerative Colitis Endoscopic Index of Severity ≤ 1 (16.4 ng/mg) were also significantly higher than in patients with Ulcerative Colitis Endoscopic Index of Severity ≥ 2 (4.63 ng/mg) (P = 0.047). In the sigmoid colon, the concentration of Ac‐5‐ASA was higher in patients with MES of 0 (21.2 ng/mg) than in patients with MES ≥ 1 (5.81 ng/mg) (P = 0.022). Conclusions The present study showed that mucosal Ac‐5‐ASA concentrations, as well as 5‐ASA concentrations, are higher in UC patients with endoscopic remission. Ac‐5‐ASA may be useful for a biomarker of 5‐ASA efficacy.

show abstract

Section: Methodsmentioning

confidence: 91%

Mucosal concentrations of N‐acetyl‐5‐aminosalicylic acid related to endoscopic activity in ulcerative colitis patients with mesalamine

Fukuda

Takabayashi

Hagihara

et al. 2020

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…Thus, CD patients with active SB lesions can exhibit "Real Silent CD" coupled with a normal CRP or FCP range. 18 For this reason, I emphasize the importance of assessing SB lesions in patients with CD using imaging modalities such as endoscopy, magnetic resonance enterography (MRE), or ultrasound. The International Organization for the Study of IBD (IOIBD) states that although CRP and FCP are useful adjunctive biomarkers, they should not be used as treatment targets because normalization of these biomarkers alone is not sufficient.…”

Section: Features Of Sb Lesions In Patients With CDmentioning

confidence: 99%

“…Thus, CD patients with active SB lesions can exhibit “Real Silent CD” coupled with a normal CRP or FCP range [ 18 ]. For this reason, I emphasize the importance of assessing SB lesions in patients with CD using imaging modalities such as endoscopy, magnetic resonance enterography (MRE), or ultrasound.…”

Section: Features Of Sb Lesions In Patients With CDmentioning

confidence: 99%

Clinical management for small bowel of Crohn’s disease in the treat-to-target era: now is the time to optimize treatment based on the dominant lesion

Watanabe

2020

Intest Res

Self Cite

View full text Add to dashboard Cite

A treat-to-target strategy, in which treatment is continuously adjusted according to the results of scheduled objective monitoring, is optimal for patients with Crohn’s disease (CD) in the era of biologics. The small bowel is a common site of intractable CD, which may result from multiple strictures or expanding lesions. To improve the prognosis of patients with small bowel CD, lesions should be proactively monitored within the subclinical phase. Objective assessment of small bowel lesions is technically difficult, however, due to the relatively poor correlation between endoscopic activity and clinical symptoms or biomarker titers. The presence of proximal small bowel lesions and asymptomatic “Real Silent CD” must be considered. Endoscopy remains the gold standard to assess these lesions. In clinical practice, the advantages and disadvantages of each imaging modality and biomarker must be carefully weighed for appropriate application and reliable monitoring. The prevalence of small bowel lesions depends on the precision of the imaging modality used for detection. Clinical management should be based on the dominant location of the intestinal lesions rather than classical classification. Optimal strategies for detecting and treating small bowel lesions in patients with CD must be developed utilizing reliable, precise, and objective monitoring.

show abstract

“…The difficulty in the early diagnosis of CACRC due to colonic mucosal changes in long-standing UC patients is often experienced in daily clinical practice. Noninvasive objective monitoring for cancer development is helpful and advantageous for optimizing treatment strategies in UC patients (24). Abnormal hypermethylation at specific DNA sequences can serve as biomarkers for predicting diagnosis, prognosis or treatment efficacy (25).…”

mentioning

confidence: 99%

Hypermethylation of Corticotropin Releasing Hormone Receptor-2 Gene in Ulcerative Colitis Associated Colorectal Cancer

Kobayashi¹,

Matsubara²,

Nakachi³

et al. 2019

In Vivo

Self Cite

View full text Add to dashboard Cite

Background/Aim: The difficulty of early diagnosis of colitis associated colorectal cancer (CACRC) due to colonic mucosal changes in long-standing ulcerative colitis (UC) patients is often experienced in daily clinical practice. Noninvasive objective monitoring for cancer development is advantageous for optimizing treatment strategies in UC patients. We aimed to examine the epigenetic alterations occurring in CACRC, focusing on DNA hypermethylation of CpG islands. Materials and Methods: The level of DNA methylation in CpG cites was compared between CACRC and the counterpart nontumorous mucosa using Infinium HumanMethylation 450K BeadChip. Results: Our subjects included 3 males and 3 females (median age, 49.5 years). The 450K CpG site DNA methylation microarray revealed that the difference in β value (level of hypermethylation) was the highest for corcicotropin releasing hormone receptor 2 (CRHR2) between CACRC and counterpart non-tumorous mucosa. Conclusion: Detection of hypermethylation of CRHR2 may be promising for cancer screening in UC patients.

show abstract

Usefulness of fecal calprotectin by monoclonal antibody testing in adult Japanese with inflammatory bowel diseases: a prospective multicenter study

Cited by 4 publications

References 42 publications

Mucosal concentrations of N‐acetyl‐5‐aminosalicylic acid related to endoscopic activity in ulcerative colitis patients with mesalamine

Mucosal concentrations of N‐acetyl‐5‐aminosalicylic acid related to endoscopic activity in ulcerative colitis patients with mesalamine

Clinical management for small bowel of Crohn’s disease in the treat-to-target era: now is the time to optimize treatment based on the dominant lesion

Hypermethylation of Corticotropin Releasing Hormone Receptor-2 Gene in Ulcerative Colitis Associated Colorectal Cancer

Contact Info

Product

Resources

About